Cite
HARVARD Citation
Mateos, M. et al. (2019). Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 395 (10218), pp. 132-141. [Online].